{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:13:16Z","timestamp":1783710796871,"version":"3.55.0"},"reference-count":77,"publisher":"Xia & He Publishing","issue":"X","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,28]]},"DOI":"10.14218\/jcth.2018.00042","type":"journal-article","created":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T22:28:55Z","timestamp":1553466535000},"page":"1-7","source":"Crossref","is-referenced-by-count":20,"title":["Mechanisms of Hepatic Cholestatic Drug Injury"],"prefix":"10.14218","volume":"7","author":[{"given":"Tea Omanovi\u0107","family":"Kolari\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vjera","family":"Nin\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Smoli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Smoli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Y","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"key20190324222849_b1","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J Pharm Sci"},{"key":"key20190324222849_b2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.24229","article-title":"Drug-induced cholestasis","volume":"53","author":"Padda","year":"2011","journal-title":"Hepatology"},{"key":"key20190324222849_b3","doi-asserted-by":"crossref","first-page":"168905","DOI":"10.1155\/2015\/168905","article-title":"Drug induced steatohepatitis: An uncommon culprit of a common disease","volume":"2015","author":"Rabinowich","year":"2015","journal-title":"Biomed Res Int"},{"key":"key20190324222849_b4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key20190324222849_b5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20190324222849_b6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.mcna.2008.03.005","article-title":"Acute liver failure including acetaminophen overdose","volume":"92","author":"Fontana","year":"2008","journal-title":"Med Clin North Am"},{"key":"key20190324222849_b7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"key20190324222849_b8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cld.2013.07.015","article-title":"Drug-induced cholestasis","volume":"17","author":"Bhamidimarri","year":"2013","journal-title":"Clin Liver Dis"},{"key":"key20190324222849_b9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"key20190324222849_b10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"key20190324222849_b11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30105","article-title":"Epidemiology and individual susceptibility to adverse drug reactions affecting the liver","volume":"22","author":"Larrey","year":"2002","journal-title":"Semin Liver Dis"},{"key":"key20190324222849_b12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.humpath.2017.08.029","article-title":"Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center","volume":"68","author":"Ettel","year":"2017","journal-title":"Hum Pathol"},{"key":"key20190324222849_b13","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"key20190324222849_b14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0025-7125(05)70287-X","article-title":"Drug-induced liver disease","volume":"84","author":"Lewis","year":"2000","journal-title":"Med Clin North Am"},{"key":"key20190324222849_b15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"key":"key20190324222849_b16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11684-007-0012-8","article-title":"Clinical analysis of 275 cases of acute drug-induced liver disease","volume":"1","author":"Li","year":"2007","journal-title":"Front Med China"},{"key":"key20190324222849_b17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep4.1088","article-title":"Drug-induced cholestasis","volume":"1","author":"Sundaram","year":"2017","journal-title":"Hepatol Commun"},{"key":"key20190324222849_b18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol Int"},{"key":"key20190324222849_b19","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/cphy.c120007","article-title":"Nuclear receptor control of enterohepatic circulation","volume":"2","author":"Gonzalez","year":"2012","journal-title":"Compr Physiol"},{"key":"key20190324222849_b20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.113.054205","article-title":"Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump","volume":"42","author":"Rodrigues","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"key20190324222849_b21","first-page":"106","article-title":"Bile acids as drugs: principles, mechanisms of action and formulations","volume":"27","author":"Hofmann","year":"1995","journal-title":"Ital J Gastroenterol"},{"key":"key20190324222849_b22","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med"},{"key":"key20190324222849_b23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s10354-008-0592-1","article-title":"Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases","volume":"158","author":"Trauner","year":"2008","journal-title":"Wien Med Wochenschr"},{"key":"key20190324222849_b24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2006-960172","article-title":"MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes","volume":"27","author":"Trauner","year":"2007","journal-title":"Semin Liver Dis"},{"key":"key20190324222849_b25","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3748\/wjg.v18.i36.4985","article-title":"Novel insight into mechanisms of cholestatic liver injury","volume":"18","author":"Woolbright","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key20190324222849_b26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1172\/JCI117579","article-title":"Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes","volume":"94","author":"Patel","year":"1994","journal-title":"J Clin Invest"},{"key":"key20190324222849_b27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/03602530903492004","article-title":"Role of the bile salt export pump, BSEP, in acquired forms of cholestasis","volume":"42","author":"Stieger","year":"2010","journal-title":"Drug Metab Rev"},{"key":"key20190324222849_b28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.110.165852","article-title":"Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes","volume":"334","author":"Lee","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"key20190324222849_b29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","article-title":"Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver","volume":"118","author":"Stieger","year":"2000","journal-title":"Gastroenterology"},{"key":"key20190324222849_b30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-2275(20)43096-2","article-title":"Mechanisms for the intestinal absorption of bile acids","volume":"9","author":"Dietschy","year":"1968","journal-title":"J Lipid Res"},{"key":"key20190324222849_b31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/bj3540591","article-title":"Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats","volume":"354","author":"Yasumiba","year":"2001","journal-title":"Biochem J"},{"key":"key20190324222849_b32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/17425255.2014.884069","article-title":"Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools","volume":"10","author":"de Lima Toccafondo Vieira","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20190324222849_b33","first-page":"1237","article-title":"Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis","volume":"145","author":"Mauad","year":"1994","journal-title":"Am J Pathol"},{"key":"key20190324222849_b34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/mol.110.067256","article-title":"Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3\/ABCB4","volume":"79","author":"Yoshikado","year":"2011","journal-title":"Mol Pharmacol"},{"key":"key20190324222849_b35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3748\/wjg.14.38","article-title":"Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump","volume":"14","author":"Meier","year":"2008","journal-title":"World J Gastroenterol"},{"key":"key20190324222849_b36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20190324222849_b37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N Engl J Med"},{"key":"key20190324222849_b38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(02)00107-1","article-title":"Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan","volume":"37","author":"Fouassier","year":"2002","journal-title":"J Hepatol"},{"key":"key20190324222849_b39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0300-483X(01)00459-0","article-title":"Role of MRP2 and GSH in intrahepatic cycling of toxins","volume":"167","author":"Dietrich","year":"2001","journal-title":"Toxicology"},{"key":"key20190324222849_b40","first-page":"1561","article-title":"The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats","volume":"29","author":"Kostrubsky","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"key20190324222849_b41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(01)00460-7","article-title":"Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate","volume":"167","author":"Funk","year":"2001","journal-title":"Toxicology"},{"key":"key20190324222849_b42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"Funk","year":"2001","journal-title":"Mol Pharmacol"},{"key":"key20190324222849_b43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1600-0773.2001.d01-147.x","article-title":"Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)","volume":"89","author":"Bramow","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"key20190324222849_b44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2003.12.001","article-title":"Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat","volume":"40","author":"Denk","year":"2004","journal-title":"J Hepatol"},{"key":"key20190324222849_b45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/jhep.2001.23501","article-title":"Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver","volume":"33","author":"Soroka","year":"2001","journal-title":"Hepatology"},{"key":"key20190324222849_b46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/jhep.2001.26213","article-title":"Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver","volume":"34","author":"Donner","year":"2001","journal-title":"Hepatology"},{"key":"key20190324222849_b47","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2174\/092986708785132870","article-title":"Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development","volume":"15","author":"Zhou","year":"2008","journal-title":"Curr Med Chem"},{"key":"key20190324222849_b48","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/jcph.671","article-title":"Importance of hepatic transporters in clinical disposition of drugs and their metabolites","volume":"56","author":"Patel","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"key20190324222849_b49","doi-asserted-by":"crossref","first-page":"46400","DOI":"10.1074\/jbc.M107041200","article-title":"Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)","volume":"276","author":"Zelcer","year":"2001","journal-title":"J Biol Chem"},{"key":"key20190324222849_b50","author":"MRP3 (multidrug resistance-associated protein 3)"},{"key":"key20190324222849_b51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","author":"Stieger","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"key20190324222849_b52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-2007-1007226","article-title":"Sinusoidal (basolateral) bile salt uptake systems of hepatocytes","volume":"16","author":"Hagenbuch","year":"1996","journal-title":"Semin Liver Dis"},{"key":"key20190324222849_b53","first-page":"331","article-title":"Electrogenicity of Na(+)-coupled bile acid transporters","volume":"70","author":"Weinman","year":"1997","journal-title":"Yale J Biol Med"},{"key":"key20190324222849_b54","first-page":"1204","article-title":"Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity","volume":"291","author":"Kim","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"key20190324222849_b55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/jhep.2000.8539","article-title":"Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2","volume":"32","author":"Fattinger","year":"2000","journal-title":"Hepatology"},{"key":"key20190324222849_b56","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"key20190324222849_b57","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"key":"key20190324222849_b58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2008-1040568","article-title":"Inborn errors of bile acid synthesis","volume":"7","author":"Setchell","year":"1987","journal-title":"Semin Liver Dis"},{"key":"key20190324222849_b59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10545-010-9259-3","article-title":"Disorders of bile acid synthesis","volume":"34","author":"Clayton","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"key20190324222849_b60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2012.11.002","article-title":"Drug-induced cholestasis","volume":"17","author":"Bjornsson","year":"2013","journal-title":"Clin Liver Dis"},{"key":"key20190324222849_b61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol Rev"},{"key":"key20190324222849_b62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2017.09.002","article-title":"The emerging role of AMP-activated protein kinase in cholestatic liver diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacol Res"},{"key":"key20190324222849_b63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1979.tb12934.x","article-title":"The Ninth Sir Hans Krebs Lecture. Compartmentation and communication in living systems. Ligand conduction: a general catalytic principle in chemical, osmotic and chemiosmotic reaction systems","volume":"95","author":"Mitchell","year":"1979","journal-title":"Eur J Biochem"},{"key":"key20190324222849_b64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.genet.39.110304.095751","article-title":"A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine","volume":"39","author":"Wallace","year":"2005","journal-title":"Annu Rev Genet"},{"key":"key20190324222849_b65","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2174\/138945011795528877","article-title":"Mitochondria in chronic liver disease","volume":"12","author":"Grattagliano","year":"2011","journal-title":"Curr Drug Targets"},{"key":"key20190324222849_b66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03602532.2011.604086","article-title":"Central role of mitochondria in drug-induced liver injury","volume":"44","author":"Pessayre","year":"2012","journal-title":"Drug Metab Rev"},{"key":"key20190324222849_b67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jinorgbio.2017.04.016","article-title":"Aluminum chloride caused liver dysfunction and mitochondrial energy metabolism disorder in rat","volume":"174","author":"Xu","year":"2017","journal-title":"J Inorg Biochem"},{"key":"key20190324222849_b68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","article-title":"Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity","volume":"67","author":"Fromenty","year":"1995","journal-title":"Pharmacol Ther"},{"key":"key20190324222849_b69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-642-00663-0_11","article-title":"Mitochondrial involvement in drug-induced liver injury","author":"Pessayre","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"key20190324222849_b70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yexcr.2015.05.002","article-title":"Bone marrow mononuclear cell transplantation improves mitochondrial bioenergetics in the liver of cholestatic rats","volume":"336","author":"de Andrade","year":"2015","journal-title":"Exp Cell Res"},{"key":"key20190324222849_b71","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"key":"key20190324222849_b72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/57.1.177","article-title":"Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy","volume":"57","author":"Rolo","year":"2000","journal-title":"Toxicol Sci"},{"key":"key20190324222849_b73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/jhep.2001.22702","article-title":"Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition","volume":"33","author":"Yerushalmi","year":"2001","journal-title":"Hepatology"},{"key":"key20190324222849_b74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.cdd.4400560","article-title":"Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation","volume":"6","author":"Rodrigues","year":"1999","journal-title":"Cell Death Differ"},{"key":"key20190324222849_b75","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/S0021-9258(18)83116-7","article-title":"Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria","volume":"264","author":"Broekemeier","year":"1989","journal-title":"J Biol Chem"},{"key":"key20190324222849_b76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.06.001","article-title":"Mitochondrially-mediated toxicity of bile acids","volume":"203","author":"Palmeira","year":"2004","journal-title":"Toxicology"},{"key":"key20190324222849_b77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/HMER.S116852","article-title":"Targeted transplantation of mitochondria to hepatocytes","volume":"8","author":"Gupta","year":"2016","journal-title":"Hepat Med"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2018.00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:17Z","timestamp":1783707437000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2018.00042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":77,"journal-issue":{"issue":"X","published-online":{"date-parts":[[2019,3,25]]},"published-print":{"date-parts":[[2019,3,28]]}},"alternative-id":["10.14218\/JCTH.2018.00042"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2018.00042","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]}}}